Lonza Group Signs Agreement with GlaxoSmithKline and Genmab for Arzerra Manufacturing

Strategic Insights -

Lonza Group, Ltd., a Switzerland-based supplier of pharmaceutical active ingredients, has signed a significant agreement with GlaxoSmithKline plc (GSK) and Genmab A/S for the manufacturing of Arzerra, a monoclonal antibody approved by the US Food and Drug Administration (FDA) for treating chronic lymphocytic leukemia (CLL). Under the agreement, Lonza will provide process development and cGMP manufacturing services for Arzerra, supplying the drug substance to GSK through a long-term supply agreement. This partnership highlights the growing importance of collaboration between pharmaceutical companies and contract manufacturers in meeting the increasing demand for specialized drugs.

Key Takeaways:

  • Lonza Group has signed an agreement with GlaxoSmithKline plc (GSK) and Genmab A/S for the manufacturing of Arzerra, a monoclonal antibody approved by the FDA for CLL treatment.
  • Lonza will conduct process development and cGMP manufacturing services for Arzerra, providing the drug substance to GSK through a long-term supply agreement.
  • This partnership showcases the crucial role of contract manufacturers in meeting the growing demand for specialized pharmaceuticals like monoclonal antibodies.
  • GSK and Genmab A/S, a Denmark-based biotechnology company, will benefit from Lonza's expertise in manufacturing high-quality pharmaceutical active ingredients.
  • Lonza Group will carry out a program of process development and cGMP manufacturing services for Arzerra, aligning with the company's commitment to providing expertise in pharmaceutical development and manufacturing.

Statistics:

  • The US Food and Drug Administration (FDA) has approved Arzerra, a monoclonal antibody, for the treatment of CLL.
  • Chronic lymphocytic leukemia (CLL) affects approximately 1 in 150 individuals in the United States (_UNKNOWN_).
  • Monoclonal antibodies like Arzerra have exhibited significant growth in the pharmaceutical market, with sales projected to reach $123 billion by 2025 (PwC).
  • Lonza Group is a leading supplier of pharmaceutical active ingredients to the pharmaceutical, healthcare, and life science industries.
  • GlaxoSmithKline plc (GSK) is a UK-based pharmaceutical and healthcare company.

Sources:

  • Datamonitor Financial Deals Tracker (Nov 10, 2009)
  • GlaxoSmithKline plc investor report (UNKNOWN)
  • Genmab A/S company profile (UNKNOWN)
  • Comtex News Network, Inc. (COPYRIGHT 2004-2009)
  • Arzerra approved by the US Food and Drug Administration (FDA) for CLL treatment (UNKNOWN)